A review of the pharmaceutical R&D efficiency : costs, timelines, and probabilities
- It is known that the costs related with drug research and development (R&D) and the timelines to develop a new drug increased over the past years. In parallel, the success rates of drug projects along the pharmaceutical R&D phases are still very low, and the outcome of all R&D efforts is stagnating. In consequence, the R&D efficiency defined as the financial investment per drug has been steadily decreasing. As innovation is the major growth driver of the pharmaceutical industry, reliable data on R&D efficiency and new concepts to overcome these challenges are of great interest for R&D managers and the sustainability of the pharmaceutical industry as a whole. This book chapter reviews publications on R&D performance indicators of the past years, such as the success rates and timelines per phase. Additionally, it illustrates the factors influencing the success rates, timelines, and costs of pharmaceutical R&D most and, thus, the denominators of the R&D efficiency.
| Author of HS Reutlingen | Schuhmacher, Alexander |
|---|---|
| DOI: | https://doi.org/10.1002/9783527693405.ch4 |
| ISBN: | 978-3-527-69340-5 |
| Published in: | Value creation in the pharmaceutical industry : the critical path to innovation |
| Publisher: | Wiley |
| Place of publication: | Weinheim |
| Editor: | Alexander SchuhmacherORCiD |
| Document Type: | Book chapter |
| Language: | English |
| Publication year: | 2016 |
| Tag: | R&D efficiency; R&D timelines; costs of drug development; success rates of pharmaceutical R&D |
| Page Number: | 19 |
| First Page: | 61 |
| Last Page: | 79 |
| PPN: | Im Katalog der Hochschule Reutlingen ansehen |
| DDC classes: | 330 Wirtschaft |
| 540 Chemie | |
| Open access?: | Nein |
| Licence (German): |  In Copyright - Urheberrechtlich geschützt |
